GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.

Rea, Nicolas et al.·Frontiers in clinical diabetes and healthcare·2025·low-moderateMeta-Analysis
RPEP-13222Meta Analysislow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Meta-Analysis
Evidence
low-moderate
Sample
N=5 preclinical studies
Participants
Human pancreatic beta cells in laboratory culture (preclinical)

What This Study Found

GLP-1 receptor agonists reduced pancreatic beta cell death by about 10 percentage points in preclinical models, supporting the idea that these drugs help preserve insulin-producing cells.

Key Numbers

Pooled mean difference in apoptosis: -0.10 (95% CI -0.15 to -0.05, p = 0.0003). 5 studies included. I-squared = 100% (extreme heterogeneity). Egger's test p = 0.80 (no publication bias detected).

How They Did This

Systematic review and meta-analysis following PRISMA guidelines. Searched Scopus, PubMed, Embase, and Google Scholar. Included preclinical studies of GLP-1 RA effects on human beta cell apoptosis. Random-effects model.

Why This Research Matters

Diabetes involves the gradual loss of beta cells that make insulin. If GLP-1 drugs can slow this loss, they may do more than just control blood sugar. They could help protect the pancreas itself.

What This Study Doesn't Tell Us

Only five studies met criteria. Extreme heterogeneity (I-squared = 100%) limits confidence in the pooled estimate. All preclinical data from cell cultures. No human clinical evidence. Long-term effects on beta cell function unknown.

Trust & Context

Original Title:
GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.
Published In:
Frontiers in clinical diabetes and healthcare, 6, 1579961 (2025)
Database ID:
RPEP-13222

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Combines results from multiple studies to find an overall pattern.

What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13222·https://rethinkpeptides.com/research/RPEP-13222

APA

Rea, Nicolas; Ramdass, Prakash V A K. (2025). GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.. Frontiers in clinical diabetes and healthcare, 6, 1579961. https://doi.org/10.3389/fcdhc.2025.1579961

MLA

Rea, Nicolas, et al. "GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.." Frontiers in clinical diabetes and healthcare, 2025. https://doi.org/10.3389/fcdhc.2025.1579961

RethinkPeptides

RethinkPeptides Research Database. "GLP-1 receptor agonists and pancreatic beta cell apoptosis i..." RPEP-13222. Retrieved from https://rethinkpeptides.com/research/rea-2025-glp1-receptor-agonists-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.